Repironics buys out UK distributor
This article was originally published in Clinica
US company Respironics is to acquire its UK distributor of 15 years, Profile Therapeutics. The Murrysville, Pennsylvania company agreed to buy all outstanding shares of Profile, at a price of 50.9p ($0.93) per share. The total value of the transaction is estimated at $46m. The combined annual revenues of the two companies add up to approximately $745m.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.